Leadless pacing systems: A valuable alternative for patients with severe access problems

Sideris, Skevos; Archontakis, Stefanos; Vaina, Sophia; Stroumpouli, Evangelia; Koumallos, Nikolas; Gatzoulis, Konstantinos; Trachanas, Konstantinos; Leontsinis, Ioannis; Sfendouraki, Elissavet; Sotiropoulos, Ilias; Tousoulis, Dimitrios; Kallikazaros, Ioannis

doi:10.1016/j.hjc.2017.11.001

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 72-year-old man with a thrombosed venous stent, renal failure, and myelodysplastic syndrome presented with second-degree AV block. A leadless pacemaker was preferred (Micra™) because of limited venous access and a high risk of infection due to his immunocompromised condition [47].…”

Section: Limited or Occluded Venous Accessmentioning

confidence: 99%

Leadless Pacemakers

Magnusson¹,

Pergolizzi²,

LeQuang³

2019

Cardiac Pacing and Monitoring - New Methods, Modern Devices

View full text Add to dashboard Cite

Leadless or transcatheter pacemakers have recently been introduced to market with important benefits and some limitations. Implanted entirely within the right ventricle, these devices eliminate the need for transvenous pacing leads and pacemaker pockets and thus reduce the risk of infections and lead-related problems. Currently, they offer only VVI/R pacing and they cannot provide atrial sensing, antitachycardia pacing, or AV synchrony. They offer a number of features (such as rate response) and electrogram storage, albeit more limited than in a transvenous system. Real-world clinical data are needed to better comment on projected battery life, which manufacturers suggest will be at least equivalent to transvenous devices. Extracting an implanted leadless pacemaker remains a challenge, although proprietary snare and removal systems are available. However, a leadless pacemaker at end of service may be programmed to OOO and left in place; a revised device may be implanted adjacent. These innovative new devices may have important uses in special populations. Initial data on implant success and adverse events are favorable. Currently, there are two leadless pacemakers available: the Micra™ device by Medtronic and the Nanostim™ device by Abbott (formerly St. Jude Medical).

show abstract

Section: Limited or Occluded Venous Accessmentioning

confidence: 99%